Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects.
BACKGROUND
Although insulin resistance (IR) is present in non-diabetic subjects, it is unknown whether IR affects statin treatment. We assessed the relationship between IR and the changes of lipid profile in patients with hyperlipidemia treated by atorvastatin.


METHODS
Forty-four non-diabetic patients were included. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. We used the value of 2.5 as the threshold for IR.


RESULTS
High-density lipoprotein (HDL) cholesterol at baseline was lower and triglyceride (TG) at baseline was higher in the IR group than in the nonIR group (p < 0.05). Changes in all lipid measurements did not differ between the two groups. HOMA-IR was correlated with HDL cholesterol at baseline and at follow-up and correlated with TG at baseline and at follow-up (r = -0.40, r = -0.53, r = 0.38, r = 0.35, p < 0.01, respectively). However, HOMA-IR did not associate with changes in total cholesterol, low-density lipoprotein cholesterol, HDL cholesterol, and TG.


CONCLUSIONS
The IR did not affect the degree of reduction in cholesterol by atorvastatin in non-diabetic subjects. The IR may influence hypertriglyceridemia greater than the effect of atorvastatin in non-diabetic subjects.
Yoshitomi
Yuji
Y
Miyauchi Makoto Memorial Clinic, Shizuoka, Japan. ytommy@sage.ocn.ne.jp
Ishii
Toshikazu
T
Kaneki
Masashi
M
Tsujibayashi
Takashi
T
Sakurai
Shun-ichiro
S
Nagakura
Chieko
C
Miyauchi
Atsuyoshi
A
D000368:Aged; D000069059:Atorvastatin; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000503:physiopathology; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin